Current and Emerging First-line Therapies in Renal Clear-cell Cancer - Tegos, Theodoros;Raptis, Athanasios;Dimitriadis, George
18,99 €
inkl. MwSt.

Versandfertig in 6-10 Tagen
payback
9 °P sammeln
  • Broschiertes Buch

Currently, 7 targeted agents and the combination of nivolumab/ipilimumab have been approved as first-line therapy for mccRCC. Sunitinib and pazopanib are the most effective first-line options, especially in favorable- and indermediate-risk patients. Nivolumab/ipilimumab seem to be the preferred first-line therapy in poor-risk patients, although cabozantinib, temsirolimus, sunitinib and pazopanib are also recommended. HD IL-2 remains a reasonable first-line treatment option in selected, favorable-risk younger patients with good performance status. The combination of ICI/VEGF-TKI is currently…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Currently, 7 targeted agents and the combination of nivolumab/ipilimumab have been approved as first-line therapy for mccRCC. Sunitinib and pazopanib are the most effective first-line options, especially in favorable- and indermediate-risk patients. Nivolumab/ipilimumab seem to be the preferred first-line therapy in poor-risk patients, although cabozantinib, temsirolimus, sunitinib and pazopanib are also recommended. HD IL-2 remains a reasonable first-line treatment option in selected, favorable-risk younger patients with good performance status. The combination of ICI/VEGF-TKI is currently underway. Combinations of pembrolizumab/axitinib, avelumab/axitinib, atezolizumab/bevacizumab and pembrolizumab/lenvatinib seem to introduce the mccRCC therapy in a new auspicious era.
Autorenporträt
Dr Theodoros Tegos holds a PhD degree on "First-line therapies in metastatic clear-renal cell carcinoma". Currently he is working in the Oncological Department of the Evangelismos General Hospital in Athens, Greece. His specialty is Oncology.